Glutathione Dosing: What The Actual Studies Used, And What That Means For Your Wallet

Last updated: June 2026. Every dose number below comes from a published human study you can look up yourself.

Search “glutathione dose” and most of what turns up is a number floating in space, no study attached, no way to check it. This piece works backward from that problem. It starts with the actual doses researchers gave real people, attaches the study design and the result to each one, and grades how much that dose should actually influence a decision. The rule is simple: a dose is only as good as the study behind it, so a dosing number without a study attached is really just marketing copy wearing a lab coat.

One definition before the numbers, because it does a lot of the work below. A dose gets a strong grade only when a controlled human study used it and tracked a real outcome. A dose pulled from a small uncontrolled study, or one that only nudged a blood marker rather than an outcome a person would notice, gets marked down, no matter how many times it shows up on a supplement label.

The landscape: every route, side by side

Route and goal	Dose used in human studies	Study design behind it	What it changed	Evidence grade
Oral, plain capsule, any goal	up to ~3 g single dose	Pharmacokinetic study in healthy adults [P1]	Blood glutathione did not meaningfully rise; availability “negligible”	Strong evidence the dose fails to get in
Oral liposomal, antioxidant/immune markers	daily for 1 month	Small controlled study, healthy adults [P2]	Whole-blood glutathione up ~40%; some oxidative-stress and immune markers improved	Moderate, surrogate markers only
Oral, skin lightening	~250 to 500 mg/day, a few weeks	Small randomized trials [P4]	Small, variable drop in skin melanin index; fades after stopping	Weak to moderate, inconsistent
Oral, liver (NAFLD)	300 mg/day, 4 months	Open-label, single-arm pilot, 34 patients [P5]	ALT fell modestly and significantly	Weak, no control group
IV, Parkinson’s	1,400 mg, 3x/week, 4 weeks	Randomized, double-blind, placebo-controlled pilot [P6]	No significant benefit over placebo	Strong evidence of no clear benefit at this dose
Intranasal, Parkinson’s	100 to 200 mg, 3x/day, 3 months	Phase IIb randomized trial, 45 patients [P7]	Improved, but not better than placebo	Strong evidence of no clear benefit at this dose
IV, skin lightening / cosmetic	no validated dose	No controlled efficacy trials [P4]	Benefit short-lived; serious safety concerns reported	No reliable dose to cite

Look at the right-hand column before anything else. The strongest evidence in that whole table isn’t a success story. It’s the finding that a plain oral dose doesn’t absorb, and that the two best-run disease trials didn’t beat placebo. The good data and the disappointing results sit in the same row. That’s the pattern worth understanding before spending a dollar on any of this.

See also: Health Sciencesforum .Com – Join the Discussions on Health Sciences at Health Sciences Forum

The tradeoff nobody prints on the label: cheap-and-uncertain versus expensive-and-tested

Here’s a way to see the table that a marketer wouldn’t choose: sort it by what it costs you, not by what body part it’s aimed at.

Cheap and oral. A capsule at 250 to 500 mg for skin, or 300 mg for liver enzymes, costs very little and carries weak-to-moderate evidence, meaning a small effect that may or may not hold up. Low stakes, low certainty.

A step up: liposomal oral. Costs more than a plain capsule, and for good reason: a 2018 study found daily liposomal glutathione raised whole-blood glutathione about 40 percent in a month, plus some improvement in oxidative-stress and immune markers [P2]. That’s a formulation actually earning its price premium over a plain capsule, which brings us to why the plain capsule doesn’t work at all.

The expensive tier: IV. This is where the tradeoff gets stark. IV glutathione for Parkinson’s, tested at 1,400 mg three times a week for four weeks in a properly randomized, placebo-controlled trial, showed no benefit over placebo [P6]. Intranasal, at 100 to 200 mg three times daily for three months, also failed to beat placebo despite patients improving on both arms [P7]. These are the priciest, most clinically monitored routes on the list, and they’re the ones with the clearest “didn’t work” data behind them.

The riskiest tier: IV for skin. No controlled trials have ever defined an effective cosmetic dose here [P4]. Add in the pharmacology: a 1991 study clocked glutathione’s plasma half-life after IV infusion at roughly 14 minutes [P3]. Whatever goes into the vein is largely gone within the hour. Paying premium prices for a route with no validated dose and a documented safety history that includes anaphylaxis and liver injury [P4] is the worst version of this tradeoff: highest cost, least evidence.

Why the oral capsule fails before it starts

The foundation of this whole scorecard is a 1992 study: healthy adults took a single oral dose of roughly 3 grams, a genuinely large amount, and researchers tracked blood glutathione over the following hours. It barely moved. The paper’s conclusion was blunt: systemic availability is “negligible in man,” and dietary glutathione is “not a major determinant of circulating glutathione” [P1]. The reason is digestive. Glutathione is a peptide, and gut and liver enzymes, mainly gamma-glutamyltransferase, chew it up before it reaches the bloodstream. So a large oral dose is really a large dose to your gut, not your tissues. That’s why liposomal formulations exist at all, and why the next row on the table looks so different.

The liposomal middle ground, and its ceiling

The liposomal study mentioned above is a genuinely useful data point: a protected delivery system moved a number the plain capsule couldn’t touch [P2]. But look closely at what moved. It was a blood level and some lab markers, in a small group, over one month, with no disease outcome measured. A surrogate marker like this is a stand-in, and stand-ins have a mixed track record of predicting whether someone actually feels or functions better. So the liposomal dose earns credit for solving the absorption problem, and a moderate grade, not a strong one, for everything after that.

Skin and liver: real but modest, and worth reading the fine print

The skin-lightening literature is where most of the “250 to 500 mg” advice online originates. A 2025 narrative review described “significant but variable decreases in melanin levels with limited side effects” from oral glutathione, while flagging inconsistency across studies and calling for “rigorous, large-scale clinical trials” [P4]. Translation: a real but small effect, at a modest dose, that varies from person to person and study to study, and tends to fade once someone stops taking it.

The liver data rests on one 2017 pilot: 34 people with NAFLD took 300 mg daily for four months, and ALT (a liver enzyme) dropped modestly and significantly [P5]. Promising, but open-label with no comparison group, so there’s no way to rule out that lifestyle changes or the natural course of the disease did some of that work. Even the study’s authors called for controlled follow-up. Weak grade, real potential.

The reasonable pick: track it instead of guessing at it

None of the doses above tell you what will happen for you specifically, because that was never the question the studies were built to answer. They report averages across groups. The only way to get information about your own results is to write them down.

That’s the one piece of advice this whole scorecard actually supports without qualification: log the dose, the route, the date, and whatever you notice, however small. An app such as the FormBlends tracker exists for exactly this, purely as a logging tool, no prescription attached, no purchase involved. A logged record turns “I think it’s helping” into an actual pattern a clinician can look at, which is a meaningfully better starting point for adjusting a dose than memory alone.

Sourcing matters as much as the number on the label

A dose is only meaningful if what’s actually in the vial matches what’s on the label. This category has a documented case where dietary-grade glutathione powder, never meant for injection, was pressed into injectable products and made people sick. An “accurate dose” of a poorly sourced product isn’t accurate at all; it’s a guess with extra steps.

For anyone moving past oral supplements toward compounded or injectable glutathione, the safer version of that route runs through a licensed clinician who sets the dose and a licensed pharmacy that compounds it to a verifiable standard, rather than an unsupervised infusion or an unlabeled vial. That doesn’t upgrade any of the evidence grades above; the table is the table. It just means the dose a person is told they’re getting is more likely to be the dose they actually receive.

Injectable glutathione is not FDA-approved for skin lightening or any cosmetic use.

Common questions

Which glutathione dose has the strongest evidence behind it? Ironically, the strongest evidence in this whole scorecard is a negative finding. A plain oral dose, even at roughly 3 grams, fails to meaningfully raise blood glutathione [P1], and the two best-designed disease trials, IV and intranasal for Parkinson’s, didn’t outperform placebo at the doses tested [P6][P7]. The cleanest positive signal belongs to a daily liposomal oral dose that raised blood levels in a small study, though only on a surrogate marker, not a health outcome [P2].

Why does liposomal glutathione get a better grade than a regular capsule at similar milligrams? Because the grade tracks whether the dose actually reaches your bloodstream, not what’s printed on the bottle. Plain glutathione gets broken down by gut and liver enzymes before it can be absorbed [P1], so the label number overstates what your body receives. A liposomal format is built to survive digestion, which is exactly why a daily liposomal dose raised whole-blood glutathione by about 40 percent while a plain capsule at a much higher dose did essentially nothing [P2].

Is there a proven IV glutathione dose for skin lightening? No. No controlled trials have ever established an effective infusion dose for cosmetic use, and a 2025 review noted the benefit is short-lived and comes with real safety concerns, including anaphylaxis and liver injury [P4]. The chemistry works against it too: IV glutathione’s plasma half-life is only about 14 minutes, so any infused dose spikes and clears almost immediately [P3].

What doses did the skin and liver studies actually use? The skin-lightening trials clustered around 250 to 500 mg daily for a few weeks, producing small, inconsistent, reversible drops in melanin [P4]. The one liver pilot used 300 mg daily for four months and saw ALT fall modestly, but without a control group to rule out other explanations [P5]. Both sit in the low hundreds of milligrams, not grams, and both carry weak-to-moderate grades.

If the studies already report what works, why bother logging my own dose? Because those numbers are group averages, and they can’t tell you how a specific dose lands for you, which was never the question the researchers were asking. Glutathione’s effects are subtle enough that relying on memory is unreliable. Writing down the dose, route, date, and any noticeable change, using something like the FormBlends tracker app, builds an actual record to bring to a clinician, turning a dose change into an evidence-based decision instead of a shot in the dark.

What exactly is a glutathione injection, and how is it different from a supplement you swallow?

A glutathione injection puts reduced glutathione straight into a vein (IV) or muscle (IM), skipping the digestive system entirely. Oral glutathione gets broken down in the gut before much of it reaches the bloodstream, which caps how much actually gets absorbed. Injections avoid that bottleneck, which is why most researchers studying real clinical effects use IV or IM delivery rather than pills.

How much glutathione do studies actually inject, and does the amount change depending on the goal?

The doses in published research swing quite a bit depending on what was being measured. Neurological and cardiovascular studies have used roughly 600 mg to 1,200 mg per IV session, while some skin-tone studies tested 600 mg given two to three times a week. There’s no single agreed-upon therapeutic dose, and what’s appropriate for any one person depends on body weight, overall health, and the condition being addressed.

Are glutathione injections safe, and what does the evidence say about the risks?

Short courses of IV and IM glutathione have generally been well tolerated in clinical studies, with few serious side effects reported at doses up to around 1,200 mg. Long-term safety data, though, are thin, and unsupervised use carries real risks: infection at the injection site, vein damage, allergic reactions. The FDA has also warned against certain unregulated IV infusion products, which is exactly why oversight from a licensed prescriber matters here.

How many injections does a typical protocol involve?

Most study protocols range from a single session up to two or three injections per week over eight to twelve weeks. There’s no universal maintenance schedule, because the research hasn’t settled on one. Clinics offering physician-supervised glutathione infusions, including those operating through a compounding pharmacy such as FormBlends, generally adjust frequency based on lab work and how the individual is responding rather than a fixed count.

References

1. The systemic availability of oral glutathione (negligible in man). European Journal of Clinical Pharmacology, 1992. https://pubmed.ncbi.nlm.nih.gov/1362956/
2. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. European Journal of Clinical Nutrition, 2018. https://pubmed.ncbi.nlm.nih.gov/28853742/ (DOI:)
3. High-dose intravenous glutathione in man: plasma half-life approximately 14 minutes. European Journal of Clinical Investigation, 1991.
4. Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review. Cureus, 2025 (PMID 40013212).
5. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study (300 mg/day, 4 months). BMC Gastroenterology, 2017.
6. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease (1,400 mg 3x/week). Movement Disorders, 2009.
7. Phase IIb study of intranasal glutathione in Parkinson’s disease (100 to 200 mg 3x/day). Journal of Parkinson’s Disease, 2017.

Written by Aisha Okafor, freelance health reporter. Cross-checking the claims against the primary sources. Last reviewed February 2026.

This article is informational. A licensed provider is the right source for personal medical advice.